Table 2. Main outcomes according to baseline treatment with inhibitors of gastric acid secretion.
| PPI (n = 207) | H2A (n = 118) | None (n = 366) | |
|---|---|---|---|
| Death | 86 (41.5) | 73 (61.9) | 159 (43.4) |
| Cardiovascular | 45 (21.7) | 30 (25.4) | 76 (20.8) |
| Infectious | 17 (8.2) | 25 (21.2) | 33 (9.0) |
| Failure to thrive-PD suspended | 10 (4.8) | 8 (6.8) | 14 (3.8) |
| Neoplasia | 3 (1.4) | 1 (0.8) | 10 (2.7) |
| Other | 11 (5.3) | 9 (7.6) | 26 (7.1) |
| Causes of infectious mortality | |||
| Peritoneal infection | 8 | 17 | 19 |
| Pulmonary infection | 3 | 1 | 11 |
| Bacterial endocarditis | 1 | 0 | 0 |
| Urinary tract infection | 0 | 2 | 0 |
| Biliary tract infection | 0 | 2 | 0 |
| Septicaemia (other/unknown origin) | 3 | 4 | 1 |
| Other | 1 | 0 | 0 |
| Peritonitis (patients suffering at least one episode) | 117 (56.5) | 70 (59.3) | 191 (52.2) |
| Peritonitis (number of episodes) | 181 (100) | 108 (100) | 289 (100) |
| Grampositives | 87 (48.1) | 52 (48.1) | 143 (49.5) |
| Gramnegatives | 35 (19.3) | 26 (24.1) | 47 (16.3) |
| Polimicrobial | 26 (14.4) | 13 (12.0) | 45 (15.6) |
| Fungal (primary) | 6 (3.3) | 5 (4.6) | 13 (4.5) |
| Mycobacteria | 0 | 0 | 1 (0.3) |
| Negative culture | 27 (14.9) | 12 (11.1) | 40 (13.8) |
| Enteric peritonitis (≥ 1 episode) | 41 (19.8) | 30 (25.4) | 61 (16.7) |
PPI: Proton pump inhibitors; H2A: H2 receptor antagonists
Figures denote number of patients (% versus total number of patients) except for the etiologic agents of peritonitis (number of episodes)